DLBCL | Clinical

Biomarker for Immune Response Identified in Relapsed/Refractory DLBCL

November 14, 2020

In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), findings from the ongoing phase 2 SPiReL study demonstrated that certain gene expressions are associated with response to DPX-Survivac plus pembrolizumab and intermittent, low-dose cyclophosphamide.

Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies

November 05, 2020

In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.